<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902352</url>
  </required_header>
  <id_info>
    <org_study_id>RRK6941</org_study_id>
    <nct_id>NCT04902352</nct_id>
  </id_info>
  <brief_title>The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer</brief_title>
  <official_title>Effect of Peri-adventitial SMA Dissection on Margin Status During Pancreaticoduodenectomy for Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Birmingham NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy&#xD;
      for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial&#xD;
      dissection has been proposed as an effective method of achieving R0 margins. There is lack of&#xD;
      standardisation of the proposed technique and no grade 1 evidence to support routine use of&#xD;
      this technique.&#xD;
&#xD;
      The goal of this randomised controlled trial is to investigate the role of routine&#xD;
      peri-adventitial dissection on the SMA margin status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the 4th cause of cancer death in Europe. With the existing treatments&#xD;
      the overall 5-year survival remains 8%. For patients with non-metastatic disease, many are&#xD;
      conventionally judged unresectable with just 10-20% eligible for upfront surgery and a 5-year&#xD;
      survival of 10-30%. Microscopically positive margins (R1) have been associated with poorer&#xD;
      survival of patients undergoing pancreaticoduodenectomy. The incidence of R1 varies between&#xD;
      16-79% in the published literature and the median survival for patients undergoing R0&#xD;
      resections is between 19-21 months versus 9-13 months for patients undergoing R1. Therefore,&#xD;
      to investigate strategies to decrease the rate of R1 resection is crucial to significantly&#xD;
      improve the patient survival1.&#xD;
&#xD;
      The SMA margin is positive in 47-77% of these resections, even when the margin is &quot;clear&quot; on&#xD;
      the pre-operative staging CT2,4. Many different techniques are in practice and have been&#xD;
      described for this part of the pancreaticoduodenectomy procedure, including the use of&#xD;
      diathermy and ties, energy devices such as Ligasure, and staplers. The main denominator is&#xD;
      staying close to the SMA and removing the so called &quot;mesopancreas&quot;3.Peri-adventitial arterial&#xD;
      dissection is a technique that has been a commune practise in several pancreatic centres and&#xD;
      has been proposed as an effective surgical technique to achieve R0 margins. On the other&#xD;
      hand, SMA dissection may theoretically increase the risk of acute haemorrhage, vascular&#xD;
      injury, and thrombosis, development of pseudo-aneurysms or persistent chyle leak due to the&#xD;
      extensive lymphoneural dissection. Furthermore, the published evidence reveal variability in&#xD;
      the definition of a &quot;positive margin&quot;, as well as the lack of accurate description of the&#xD;
      surgical technique in the majority of the studies, with only about 25% of the studies&#xD;
      reporting the use of the technique4. Moreover, none of the published studies have documented&#xD;
      standardisation in the use of the technique with regards to the extent of the periadventitial&#xD;
      dissection on the SMA, longitudinally and circumferentially.&#xD;
&#xD;
      In the University Hospitals of Birmingham NHS Trust, pancreatic surgery is centralised in&#xD;
      Queen Elizabeth Hospital. Peri-adventitial dissection is selectively performed in cases where&#xD;
      there is a close relation of the tumour to the arteries in an effort to achieve an R0&#xD;
      resection. Routine practice of peri-adventitial dissection during pancreaticoduodenectomy for&#xD;
      resectable tumours has been performed in a subset of patients based on surgeon's preference.&#xD;
      The results suggest a R1 rate of 20%, with SMA margin positivity 5%, compared to a rate of&#xD;
      44% margin positivity within the unit, with 54% SMA R1 rate. Furthermore, complication rates&#xD;
      are comparable to the average described by the unit's results and published literature (20.8%&#xD;
      of grade B and above complications as per the Clavien-Dindo classification). More&#xD;
      specifically, there have been no incidences of vascular related injury or complication&#xD;
      related to the technique; or persistent chyle leak (one episode of chyle leak grade A&#xD;
      recorded that was managed conservatively).&#xD;
&#xD;
      The goal of this prospective study is to investigate the role of routine peri-adventitial&#xD;
      dissection on the SMA margin status. Primary outcome is SMA margin status. Secondary outcomes&#xD;
      are: length of stay, complications, overall survival, disease free survival and adjuvant&#xD;
      treatment uptake.&#xD;
&#xD;
      This will be a two arm, randomised 1:1 (periadventitial dissection : no periadventitial&#xD;
      dissection) study. A pilot phase will determine feasibility to proceed with the rest of the&#xD;
      trial and to determine:&#xD;
&#xD;
        1. Feasibility of patient recruiting and randomisation&#xD;
&#xD;
        2. Feasibility and reproducibility of the technique&#xD;
&#xD;
        3. Feasibility of use of intraoperative photography&#xD;
&#xD;
        4. Intraoperative and postoperative complication rate and severity (Clavien-Dindo&#xD;
           classification)&#xD;
&#xD;
        5. Positive SMA margin status rate&#xD;
&#xD;
           Feasibility criteria to be met in order to proceed with the rest of the trial:&#xD;
&#xD;
        6. Recruitment of at least 20 patients in 6 months (both arms)&#xD;
&#xD;
        7. Periadventitial dissection technique to be performed in at least 80% of the randomised&#xD;
           patients to that arm as documented by intraoperative photography&#xD;
&#xD;
        8. Increase in the complication rate no more than 10%&#xD;
&#xD;
      For the full trial a sample size of 51 patients per arm has been based on a margin positivity&#xD;
      of 44%, based on the unit's results, and expected 60% reduction (expected R1 18%) at power&#xD;
      80% (type A error 0.05).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">October 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sealed envelope system for allocation of intervention Master list held by third party, researcher and surgical team aware of intervention Intervention NOT documented in notes making clinical follow up team, investigator and outcomes assessor blind to arm allocated</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SMA margin status</measure>
    <time_frame>Recorded at histological examination estimated 2 weeks post-operatively</time_frame>
    <description>Rate of R0 resection (defined as no tumour within 1mm from the SMA margin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Recorded at patient discharge (monitored by research team) and analysed at an expected time frame of 2 years (study end)</time_frame>
    <description>Number of days to discharge (day 0 being the day of the operation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>90 days</time_frame>
    <description>categorised by clavien-dindo (grade 1 to 5, higher score = worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adjuvant treatment</measure>
    <time_frame>within 1 year of surgery</time_frame>
    <description>percentage of patients receiving adjuvant chemotherapy, type and duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Analysis at 5 years from start of trial</time_frame>
    <description>The length of time (in months) from day of diagnosis to death or last follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Analysis at 5 years from start of trial</time_frame>
    <description>length of time (in months) from day of resection until diagnosis of recurrence or last follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Periadventitial dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from &quot;angle&quot; of the artery to the level of inferior border of the uncinate process.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO periadventitial dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No Periadventitial dissection of the SMA</intervention_name>
    <description>lymphoneural tissue around SMA left intact</description>
    <arm_group_label>NO periadventitial dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Periadventitial dissection of the SMA</intervention_name>
    <description>For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from &quot;angle&quot; of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.</description>
    <arm_group_label>Periadventitial dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult (â‰¥ 18 years old) patients with a non-metastatic (based on NCCN definition)&#xD;
             on imaging pancreatic tumour of the head or uncinate process treated with a&#xD;
             pancreaticoduodenectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. All paediatric patients (&lt; 18 years old)&#xD;
&#xD;
          2. Patients that cannot provide consent&#xD;
&#xD;
          3. All borderline, locally advanced and metastatic pancreatic tumours on imaging (based&#xD;
             on NCCN criteria)&#xD;
&#xD;
          4. All patients with a cytological or histological diagnosis of cholangiocarcinoma,&#xD;
             ampullary and duodenal carcinoma&#xD;
&#xD;
          5. All patients with benign disease or dysplasia with no evidence of malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikolaos A Chatzizacharias, FRCS</last_name>
    <phone>07787731126</phone>
    <email>Nikolaos.Chatzizacharias@uhb.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah F Powell-Brett, MRCS</last_name>
    <phone>07887754856</phone>
    <email>sarah.powell-brett1@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>County (Optional)</state>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolas A Chatzizacharias, FRCS</last_name>
      <phone>07787731126</phone>
      <email>Nikolaos.Chatzizacharias@uhb.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sarah F Powell-Brett, MRCS</last_name>
      <phone>07887754856</phone>
      <email>sarah.powell-brett1@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Birmingham NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Nikolaos Chatzizacharias</investigator_full_name>
    <investigator_title>Consultant HPB Surgeon</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>SMA dissection</keyword>
  <keyword>Superior mesenteric artery</keyword>
  <keyword>margin status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

